340B Guardian Model Overview
|
|
- Lee Brown
- 5 years ago
- Views:
Transcription
1 340B Guardian Model Overview
2 Why monitor 340B program compliance? The 340B program has grown from less than $2B in total sales in 2002 to over $8B in sales in Currently, approximately 30,000 covered entity sites participate in the program. (Source: OPA Database) 1/3 of all hospitals are now covered entities (Source: 2011 GAO Report) 1 in 4 pharmacies is now a 340B contract pharmacy; that s over 15, B contract pharmacies (Source: Very high rates of non-compliance in government audits (53% in 2012, 59% in 2013 Source: OPA audit result files) The program is projected to grow to over $16B by 2019 (Source: BRG) These same drivers of growth are also increasing the complexity of the 340B program which creates more areas of risk for diversion and duplicate discounts Page 2
3 Prohibition Against Diversion Covered entities cannot resell or transfer a 340B drug to a person who is not a patient of the entity. Current (1996) patient definition requires: Covered entity has a relationship w/individual such that the covered entity maintains records of the individual s health care Individual receives services from a health care professional who is an employee of the entity or provides care under contract or other arrangement with the entity, such that responsibility for the care provided remains with the covered entity and Individual receives care from the covered entity that is consistent with the service or range of services for which the entity receives federal grant funding Page 3
4 Prohibition Against Duplicate Discounts Manufacturers are not required to provide a discounted 340B price and a Medicaid rebate on the same drug 340B statute required HRSA to create a mechanism to ensure that manufacturers did not pay "duplicate discounts." HRSA created the Medicaid Exclusion File: The entities listed on the Exclusion File have reported that they will fill Medicaid prescriptions with 340B-purchased drugs. Claims for these prescriptions are not eligible for rebates. Some covered entities purchase drugs for their Medicaid patients outside of the 340B program ( Medicaid carve-out ). These entities are not included on the Medicaid Exclusion File. The 2011 OIG report noted that many states don t use the exclusion file. Page 4
5 Cause for Concern: HRSA Audits / GAO & OIG For audits conducted in 2012 & 2013, HRSA reported results from 126 CE audits (Source: OPA website) 56% of these audits found either diversion or duplicate discounts 52 instances of product diversion 39 instances of duplicate discounting In GAO s words: increased use of the 340B program by contract pharmacies and hospitals may result in a greater risk of drug diversion, further heightening concerns about HRSA s reliance on self-policing to oversee the program. Recent OIG Report had further troubling findings Bottom Line: Significant leakage in this channel Page 5
6 What type of numbers are we talking about? Duplicate discounts can result in manufacturer overpayments that exceed 50% of WAC Diversion results in lost revenue of 30% or greater of WAC Page 6
7 Root causes of Medicaid duplicate discounts Duplicate discounts occur for a variety of reasons Inappropriate use of OPA s Medicaid Exclusion File Only a sub-set of NPIs and Medicaid Provider Numbers are identified Or, a covered entity fails to properly include the NPI on billed outpatient drugs Managed Medicaid patients are not properly identified as requiring carve-out status Technical issues at point of dispensing in contract pharmacy arrangements Dual-eligible patients are not properly identified as requiring carve-out status State Medicaid Program s role/responsibilities to prevent claims being received from CE s and/or being sent to manufacturers Page 7
8 Duplicate discount monitoring Manufacturers can do a number of things to monitor covered entity compliance Review state claims level rebate data to identify units potentially purchased by 340B facilities (using NPI scrubbing or reimbursement tests) Calculate the percentage of total sales at a 340B price for covered entities not listed on the Medicaid Exclusion File Identify changes in Medicaid Exclusion File status that don t align with trends in chargeback volume Trend 340B chargeback volume following ACA implementation Chargebacks to Sales Ra6o Immunology Actual Ra6o Expected Ra6o % of Medicaid Pa6ents Chargebacks Sales Percen6le % 64% 35.9% 14,419 15, % % 63% 36.8% 14,974 15, % % 63% 36.8% 11,810 11, % Page 8
9 Root causes of diversion Diversion can occur in a number of different ways: Inpatient utilization Utilization at ineligible sites Utilization through ineligible physicians Utilization by ineligible patients Programmatic errors in virtual inventory management systems (e.g. incorrectly including ineligible claims data ) Page 9
10 Diversion monitoring Manufacturers can do a number of things to monitor covered entity compliance Correlate increased 340B sales (both onsite and through contract pharmacies) with newly listed non-reimbursable hospital sites Identify outlier hospitals based on benchmarking 340B sales as a percentage of total sales across all similar covered entities Trend chargebacks over time for covered entities to identify unexplained increases in 340B utilization Look for instances of shifts in utilization that correlate with new entity registrations 6,000 Oncology Chargebacks (Units) 5,000 4,000 3,000 2,000 1, Combined Shift Entity New Entity Page 10
11 BRG s Approach to Monitoring for Diversion & Duplicate Discounts Integration of manufacturer data with publicly available data Utilizing manufacturer data in isolation can lead to false positives and can overlook instances of diversion due to lack of context We supplement third party data to the manufacturer data to provide additional insight into expected levels of utilization and significant events at a covered entity Third party data can be used to find explanations for root causes of changes in chargeback data that is not inherent in manufacturer data Page 11
12 BRG s Approach to Monitoring for Diversion & Duplicate Discounts Correlation of trends in chargebacks with events at covered entities Increases in chargeback data alone could have reasonable explanations unrelated to diversion and/or duplicate discounts But increases in chargeback data with a corresponding event identified through hospital cost report data could be a stronger indication of diversion or duplicate discounts For example, a large increase in chargebacks correlated with a newly listed outpatient clinic on the non-reimbursable portion of a cost report could reflect diversion through a newly acquired physician group that is ineligible for 340B pricing Page 12
13 BRG s Approach to Monitoring for Diversion & Duplicate Discounts Benchmarking entities against peers to standardize results and flag outliers Define key statistic for comparison Standardize key statistic for each entity Entities may have different profiles and therefore comparison without adjustment could miss potential diversion or duplicate discounts or create false positives Identify outliers based off variation calculation of key statistic Distributions may not be normal and different methodologies for outlier identification may need to be used Entities identified as outliers have higher probability of diverting product or creating duplicate discounts Page 13
14 BRG s Approach to Monitoring for Diversion & Duplicate Discounts Comparison of results across numerous products Capability to group products together can be critical in determining whether trends in the chargeback data reflect a systemic issue at a hospital or an isolated event Grouping products mitigates probability of incorrectly identified diversion or duplicate discounts due to data noise For example, if a contract pharmacy is flagged for potentially diverting product for product A, but not products B, C, D, E, and F, then most likely diversion is not the root cause for the increase in chargebacks Page 14
15 340B Guardian Using the concepts outlined in the previous slides, BRG has developed a comprehensive 340B compliance monitoring model called 340B Guardian The model includes 11 modules that utilize a diverse set of metrics and analytical approaches to identify duplicate discounts and diversion Each module is designed to identify different root causes of duplicate discounts and diversion Page 15
16 Utilizing the Analytical Output Dispute resolution with state Medicaid programs In instances of duplicate discounts, manufacturers may be able to dispute historical rebates paid to state Medicaid programs Covered entity engagement Open a dialogue to better understand the analytical results and address potential ongoing diversion Highlight options for covered entities to address ongoing duplicate discounts Correcting the Medicaid Exclusion File Listing the covered entity on the Medicaid Exclusion File Properly identifying managed Medicaid patients Properly identifying dual eligibles Page 16
Aaron Vandervelde Managing Director Berkeley Research Group
Aaron Vandervelde Managing Director Berkeley Research Group Statement re Interests Aaron Vandervelde provides services as an independent consultant concerning 340B matters to pharmaceutical manufacturers
More information10/2/2015. CPAs and ADVISORS 340B: COMPLIANCE MATTERS AND HERE S WHY MICHAEL R. EARLS, CPA DIRECTOR. experience access // 2 // experience access
CPAs and ADVISORS experience access // 340B: COMPLIANCE MATTERS AND HERE S WHY MICHAEL R. EARLS, CPA DIRECTOR MATERIALS COVERED TODAY 340B Program Evolution, Purpose & Benefits HRSA & Manufacturer Audits
More informationMATERIAL COVERED TODAY
MATERIAL COVERED TODAY This presentation has been designed to discuss compliance needs, proposed changes and best practices for covered entities in the 340B Drug Pricing Program This presentation should
More informationPharmaceutical Summit on Business and Compliance Issues in Managed Markets
Pharmaceutical Summit on Business and Compliance Issues in Managed Markets TRACK A: 340B PROGRAM CONSIDERATIONS A Panel Discussion By: Agenda Panel Introductions Overview of 340B Program Compliance Considerations
More information340B Program Risk: A Perspective for Pharmaceutical Manufacturers
CiiTA Monograph Series 340B Program Risk: A Perspective for Pharmaceutical Manufacturers EXECUTIVE SUMMARY The number of ineligible prescriptions purchased through the PHS 340B Drug Discount Program represents
More information340B Drug Program Compliance: Focus on Disproportionate Hospitals
340B Drug Program Compliance: Focus on Disproportionate Hospitals Part II: 340B Drug Program Compliance: Pharmacy Operations and the DSH January 29, 2014 1 Faculty Stephen J. Weiser, JD, LLM Director 312-403-4284
More information1/16/2014. David Pointer President, SolutionsRx
David Pointer President, SolutionsRx 417.679.2203 david@pointerlaw.com 1 340B Program Overview Physician-Administered Drugs Contract Pharmacies 340B Compliance Expanding 340B Utilization 2 Federally mandated
More information340B Pharmacy Program Best Practices
340B Pharmacy Program Best Practices December 8, 2015 Agenda 1. The Program and the Requirements 2. Program Compliance and Integrity (Best Practices) Internal Controls Policies and Procedures OPA Database
More information8 th Annual Oncology Economics Summit Estimating the Impact of Recent Legislation on Future Growth in the 340B Program
8 th Annual Oncology Economics Summit Estimating the Impact of Recent Legislation on Future Growth in the 340B Program La Jolla, CA February 21-22, 2012 1 Legal Made Me Do It The opinions expressed in
More information340B Program Update & Recommendations for Monitoring Program Compliance October
340B Program Update & Recommendations for Monitoring Program Compliance October 2 2014 Speaker Biography Ray Albertina Director Deloitte & Touche LLP +1 (314) 342 4984 ralbertina@deloitte.com Ray is a
More informationChapter 9 Medicaid and 340B
Chapter 9 Medicaid and 340B A. Introduction UPDATED 1. The complex intersection of Medicaid and 340B The intersection of 340B and Medicaid is one of the most complex and significant areas within any health
More information340B Compliance, Audits & Opportunities
340B Compliance, Audits & Opportunities NW Ohio HFMA February 15, 2018 David Layne, CPA Manager HRSA Audits Bizzell Group-Silver Spring, Maryland Prior Hospital experience Many are pharmacists Experienced
More information340B Program Contract Pharmacy Self-Audit Tool: Diversion
Page 1 Purpose: The purpose of the Contract Pharmacy Self-Audit Tools is to improve contract pharmacies compliance with the 340B Program requirements. Covered entities remain responsible for the 340B drugs
More informationWebinar Schedule. I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance
Webinar Schedule I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance II. Stakeholder Response to the 340B Ceiling Price and Manufacturer CMP Proposed Rule Thursday, Oct. 8, 2005
More informationRenee Gravalin, Partner
Experience the Eide Bailly Difference 340B Drug Program Renee Gravalin, Partner rgravalin@eidebailly.com 701.799.5449 Agenda Proposed Changes 1 Experience the Eide Bailly Difference Created in 1992 to
More information340B MEGA GUIDANCE WHAT NOW? HFMA REGION 6 DECEMBER 16, 2015
340B MEGA GUIDANCE WHAT NOW? HFMA REGION 6 DECEMBER 16, 2015 Brian Bell Director bbell@bkd.com Claire Torrella Manager ctorrella@bkd.com MATERIAL COVERED TODAY The Health Resources and Services Administration
More information11/5/2015 A&A PERSPECTIVE. HFMA Region 9 Conference November 15, Tracy Young, CPA, Partner Brian Bell, Director
340B MEGA GUIDANCE FROM AN A&A PERSPECTIVE HFMA Region 9 Conference November 15, 2015 Tracy Young, CPA, Partner Brian Bell, Director 1 MATERIAL COVERED TODAY The Health Resources and Services Administration
More information6/11/2013. South Carolina Primary Health Care Association. Overview. 340B Essentials. Disclaimer. 340B Essentials. 340B Essentials
South Carolina Primary Health Care Association 2013 Clinical Network Retreat June 9, 2013 Preparing for and Surviving a 340B Audit presented by: Michael B. Glomb, Partner of Overview Key features of the
More information340B MEGA GUIDANCE WHAT NOW? KENTUCKY HFMA WINTER INSTITUTE JANUARY 21, 2016
340B MEGA GUIDANCE WHAT NOW? KENTUCKY HFMA WINTER INSTITUTE JANUARY 21, 2016 Brian Bell Director bbell@bkd.com Brenda Christman Managing Director bchristman@bkd.com MATERIAL COVERED TODAY The Health Resources
More informationThe 340B Drug Pricing Program
The 340B Drug Pricing Program Presentation at Alliance of Community Health Plans Medical Directors and Pharmacy Directors Meeting October 2012 Avalere Health LLC Avalere Health LLC The intersection of
More informationBKD NATIONAL HEALTH CARE GROUP
BKD NATIONAL HEALTH CARE GROUP PRESCRIPTION FOR 340B SUCCESS IN 2018 February 14, 2018 BRIAN BELL DIRECTOR BBELL@BKD.COM TO RECEIVE CPE CREDIT Participate in entire webinar Answer polls when they are provided
More information340B Pharmacy Program Compliance insight. ideas Kentucky Primary Care Association attention
340B Pharmacy Program Compliance Kentucky Primary Care Association Presented by: Scott Gold, CPA, Partner October 16, 2012 Brief Overview History of 340B Drug Program Discounted Pharmaceuticals Growing
More informationCOMPLIANCE IN THE 340B DRUG PRICING PROGRAM
COMPLIANCE IN THE 340B DRUG PRICING PROGRAM Jason Atlas RPh MBA Manager, Education and Compliance Support Apexus Education and Compliance Support Team Apexus Education and Compliance Support Team 1 Objectives
More informationContract Pharmacy Relationships
Contract Pharmacy Relationships What is a contract pharmacy? 1 What is a contract pharmacy? Dispenses drugs to FQHC patients on behalf of FQHC Contract between FQHC and pharmacy Typically pharmacy not
More information340B: WHAT ATTORNEYS NEED TO KNOW TODAY, TOMORROW AND IN THE FUTURE. March 3, 2016 ABA Emerging Issues in Healthcare Conference San Diego, CA
340B: WHAT ATTORNEYS NEED TO KNOW TODAY, TOMORROW AND IN THE FUTURE March 3, 2016 ABA Emerging Issues in Healthcare Conference San Diego, CA 2 Presentation Outline What you need to know Today 340B Program
More informationFollowing this presentation, attendees should be able to: Identify key events in 340B landscape that occurred in 2015 and 2016.
Following this presentation, attendees should be able to: Identify key events in 340B landscape that occurred in 2015 and 2016. Identify critical components of a compliance plan. List the different types
More informationIntroduction. The Basics of the 340B Program. 340B Drug Discount Program Compliance, Audit & Enforcement Activity. Wesley R.
340B Drug Discount Program Compliance, Audit & Enforcement Activity Wesley R. Butler Wes.Butler@BBB-Law.com Introduction Caveat This presentation is intended as an overview of a complex area of law and
More informationTHE 340B DRUG DISCOUNT PROGRAM AND INTERPLAY WITH MEDICARE AND MEDICAID REIMBURSEMENT PRINCIPLES. Barbara Straub Williams.
THE 340B DRUG DISCOUNT PROGRAM AND INTERPLAY WITH MEDICARE AND MEDICAID REIMBURSEMENT PRINCIPLES I. History and Purpose of 340B Program Barbara Straub Williams March 2015 Section 340B of the Public Health
More informationAn Introduction to and Updated Regarding the 340B Federal Drug Discount Program
An Introduction to and Updated Regarding the 340B Federal Drug Discount Program Chris Roberson, JD, MPH 317.871.0000 or 877.256.8837 Raphael Health Center Picture of CHC Describe how many centers and how
More informationContract Pharmacy Arrangements in the 340B Program. Conflicts of Interest. Learning Objectives 2/10/2014. OIG Memorandum Report:
OIG Memorandum Report: Contract Pharmacy Arrangements in the 340B Program (OEI-05-13-00431) Adam Freeman, Program Analyst U.S. Department of Health & Human Services Office of Inspector General February
More informationTable of Contents. Executive Resources, LLC 2015, v. 2
2 Table of Contents I. Introduction II. Overview III. Contract Pharmacy and Arrangements IV. HRSA and 340B Data Base V. Software, Internal Control Systems and Management of Inventory VI. External Relationships
More information340B Drug Pricing: Don t Become an HRSA Statistic. Wipfli LLP 1
340B Drug Pricing: Don t Become an HRSA Statistic October 13, 2017 Wipfli LLP 1 Today s Agenda 340B Drug Pricing Program Overview Program Benefit Eligibility Program in Operation Contract Pharmacy Regulatory
More information340B Drug Pricing Program
340B Drug Pricing Program Mary Stepanyan, PharmD Candidate 2018 University of Southern California, School of Pharmacy Pro Pharma Pharmaceutical Consultants Under the preceptorship of Dr. Craig Stern WHY
More informationWhat is the 340B Program?
Emily Cook, Partner, McDermott Will & Emery Anne S. Daly, Senior Director of Compliance, Banner Health Karolyn Woo Miles, Principal, Deloitte & Touche LLP 1 What is the 340B Program? Federal drug discount
More informationHow to Survive a HRSA Audit & Take Corrective Action. William von Oehsen, Principal Powers Pyles Sutter & Verville, PC
How to Survive a HRSA Audit & Take Corrective Action William von Oehsen, Principal Powers Pyles Sutter & Verville, PC Statement of Conflicts of Interest William von Oehsen represents 340B providers and
More informationThe 340B Program: Challenges and Opportunities
The 340B Program: Challenges and Opportunities March 2015 Thomas Barker Igor Gorlach Foley Hoag LLP Overview Overview and History of the 340B Program ACA s Changes to the 340B Program Recent Developments
More information340B Program: Mega Guidance, Mega Change Pershing Yoakley & Associates, PC (PYA).
340B Program: Mega Guidance, Mega Change No portion of this white paper may be used or duplicated by any person or entity for any purpose without the express written permission of PYA. For many years,
More informationStatement of Conflicts of Interest
Part 1 - Overview Debra A. Muscio, MBA, CHC, CCE, CFE SVP, Chief Audit, Ethics & Officer Community Medical Centers Karolyn Woo-Miles Senior Manager Deloitte & Touche LLP April 22, 2015 Statement of Conflicts
More informationMedicaid Prescription Drug Payment Reform
Medicaid Prescription Drug Payment Reform Spring 2006 NCSL Health Chairs Meeting John M. Coster, Ph.D., R.Ph. June 10, 2006 1 Community Retail Pharmacy In 2005, there were approximately 56,000 community
More informationHealth Policy Explainer
The 340B Drug Program Health Policy Explainer Created in 1992, the 340B Drug Discount Program is a little-known program that s getting an increasing amount of attention from hospitals, Congress and pharmaceutical
More information2/25/2016. Today s Objectives. Disclaimer WHAT S NEW IN THE WORLD OF 340B?
WHAT S NEW IN THE WORLD OF 340B? Jim Donnelly Vice President of Pharmacy Services Hudson Headwaters Health Network Jennifer Bolster Partner Hancock Estabrook, LLP. Friday, February 26 th Today s Objectives
More informationA Pharmacy s Guide to 340B Contract Pharmacy Services Best Practices
A Pharmacy s Guide to 340B Contract Pharmacy Services Best Prepared by: Date: September 1, 2014 Table of Contents Overview... 1 Introduction to the 340B program... 3 340B Covered Entity Eligibility...
More informationStructuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements
Presenting a live 90-minute webinar with interactive Q&A Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements WEDNESDAY, MARCH 19, 2014 1pm Eastern 12pm Central 11am
More informationATTN: Comments on 340B Drug Pricing Program Omnibus Guidance
October 27, 2015 Krista Pedley Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Rockville, MD 20857 ATTN: Comments on 340B Drug Pricing Program Omnibus
More informationCompliance Risk Areas for Health Centers: A Financial Perspective. Marcie H. Zakheim Partner
Compliance Risk Areas for Health Centers: A Financial Perspective Marcie H. Zakheim Partner DISCLAIMER This training has been prepared by the attorneys of Feldesman Tucker Leifer Fidell LLP. The opinions
More informationRE: Proposed Rule: RIN 0906-AA90, 340B Drug Pricing Program; Administrative Dispute Resolution, (Vol. 81, No. 156, August 12, 2016)
Krista Pedley, Pharm.D, MS Captain, USPHS Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane, Mail Stop 08W05A Rockville, MD 20857 RE: Proposed Rule: RIN
More informationAmerica s Voice for Community Health Care
America s Voice for Community Health Care The National Association of Community Health Centers (NACHC) represents Community and Migrant Health Centers, as well as Health Care for the Homeless and Public
More information340B Drug Discount Program: Expansion Issues, Diversion Concerns, and Implications for Price Reporting and Compliance
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. 340B Drug Discount Program: Expansion Issues,
More information340B Compliance: Overcoming Challenges with Diversion, Duplicate Discounts, and Orphan Drug Restrictions
Presenting a live 90-minute webinar with interactive Q&A 340B Compliance: Overcoming Challenges with Diversion, Duplicate Discounts, and Orphan Drug Restrictions WEDNESDAY, JANUARY 15, 2014 1pm Eastern
More informationThis training will begin at 12:00pm ET. WebEx Technical Support: Or us at
This training will begin at 12:00pm ET WebEx Technical Support: 1-866-229-3239 Or e-mail us at nationalhivcenter@fenwayhealth.org Works with HIV/AIDS service organizations and community-based organizations
More informationThe Federal 340B Drug Discount Program. Compliance and Lessons Learned. Jason Reddish September 24, 2014
The Federal 340B Drug Discount Program Compliance and Lessons Learned Jason Reddish September 24, 2014 About Me Jason Reddish Attorney Powers Pyles Sutter & Verville PC 1501 M Street NW, 7 th Floor Washington,
More informationThe Future of 340B. Disclosure
1 The Future of 340B NCPA 2018 Annual Convention Susan Pilch, JD, Senior Vice President, Legal and Advocacy, 340B Health Amanda Gaddy, RPh, Co Founder, Secure340B Disclosure Susan Pilch declares no conflicts
More information340B Contract Pharmacy Arrangements: What Does the Future Hold?
Presenting a live 90-minute webinar with interactive Q&A 340B Contract Pharmacy Arrangements: What Does the Future Hold? Structuring Arrangements, Meeting Legal and Regulatory Requirements THURSDAY, DECEMBER
More informationThe 340B drug discount program was created in 1992
Proposed Rule Changes for 340B Programs: Overview and Impact Anthony Zappa, PharmD, MBA Specialty Healthcare Benefits Council The 340B drug discount program was created in 1992 as a means for certain nonprofit
More information340B Program New Developments and Increasing Scrutiny
340B Program New Developments and Increasing Scrutiny Todd Nova Hall Render tnova@hallrender.com Wisconsin Office of Rural Health Hospital Finance Workshop August 24, 2012 What We Will Cover 2 1 340B Program
More informationInformation Maintained by the Office of Code Revision Indiana Legislative Services Agency IC Chapter 22. Pharmacy Audits
Information Maintained by the Office of Code Revision Indiana Legislative Services Agency IC 25-26-22 Chapter 22. Pharmacy Audits IC 25-26-22-1 Definitions applicable to chapter Sec. 1. The definitions
More informationFPNTC FAMILY PLANNING NATIONAL TRAINING CENTER
Demystifying 340B: Frequently Asked Questions Webinar February 13, 2018 FPNTC Responses to Unanswered Chat Questions Mindy McGrath, National Family Planning and Reproductive Health Association (NFPRHA)
More informationSteve Zielinski Regional Director SUNRx, LLC April 16, 2010
Steve Zielinski Regional Director SUNRx, LLC April 16, 2010 Mississippi Primary Care Association 340B Program Overview Contracted Pharmacy Model New Multiple Contract Pharmacy Elements Maintaining 340B
More informationBest Practices for 340B Internal Audits and Key Takeaways from the Winter 340B Coalition Conference
Best Practices for 340B Internal Audits and Key Takeaways from the Winter 340B Coalition Conference February 9, 2017 1 Webinar Panelists! The Panel! Tammy Zukowski, MBA! Douglas E. Miller, Pharm.D.! William
More informationContracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016
Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress October 20, 2016 Thomas Beimers Hogan Lovells Thomas.beimers@hoganlovells.com Sarah Franklin Covington
More informationAn Introduction to Medicare
An Introduction to Medicare Medicare can be confusing, but we re here to help you and your employees make sense of it all. This Medicare overview is a great place to start. It goes over the Medicare basics
More informationThe 340B Drug Pricing Program: Opportunities for Community Pharmacists
The 340B Drug Pricing Program: Opportunities for Community Pharmacists by Marsha K. Millonig, MBA, RPh President,Catalyst Enterprises, LLC Goals: After completing this program, participants will be able
More informationANTI-FRAUD PLAN INTRODUCTION
ANTI-FRAUD PLAN INTRODUCTION We recognize the importance of preventing, detecting and investigating fraud, abuse and waste, and are committed to protecting and preserving the integrity and availability
More informationFOCUSING YOUR REVENUE CYCLE
FOCUSING YOUR REVENUE CYCLE GAURAV GUPTA VP, PRODUCT STRATEGY AND PERFORMANCE MANAGEMENT Connect the Data Linkage of previously disparate data promotes root cause analysis & action plan development Integration
More informationCalculating Accurate Metrics for the Actuarial Cost Model. Introduction. William Bednar, FSA, FCA, MAAA
Calculating Accurate Metrics for the Actuarial Cost Model William Bednar, FSA, FCA, MAAA Introduction Calculating metrics for an actuarial model sounds simple enough (just sum up the data!), but if proper
More informationHRSA Publishes 340B Drug Pricing Program Omnibus Guidance Notice: Significant Policy Ramifications Should Trigger Public Comment
Alert Life Sciences Health Industry If you have questions or would like additional information on the material covered in this Alert, please contact one of the attorneys listed below: Joseph W. Metro Partner,
More informationManufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
More informationPayer Channel Forecasting and Analysis. Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc.
Payer Channel Forecasting and Analysis Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc. Disclaimer The views and opinions expressed in this presentation are those of
More informationNCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work
NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January 2016 The Centers for Medicare & Medicaid Services (CMS) recently issued a 658-page, oftendelayed, final rule on the
More informationDecember 20, Howard A. Zucker, M.D., J.D. Commissioner Department of Health Corning Tower Empire State Plaza Albany, NY 12237
December 20, 2017 Howard A. Zucker, M.D., J.D. Commissioner Department of Health Corning Tower Empire State Plaza Albany, NY 12237 Re: Optimizing Medicaid Drug Rebates Report 2017-F-9 Dear Dr. Zucker:
More informationSETTING A STANDARD FOR GP COMPLIANCE
SETTING A STANDARD FOR GP COMPLIANCE CURRENT LANDSCAPE AND WHAT DOES GP COMPLIANCE LOOK LIKE? MAY 9, 2017 2017 HURON CONSULTING GROUP INC. SPEAKER INTRODUCTIONS Clay Willis Director T 404-825-3319 E cwillis@huronconsultinggroup.com
More informationGERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036
Curriculum Vitae GERALD (JERRY) LEWANDOWSKI BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Direct: 202.480.2643 Mobile: 202.258.2669 jlewandowski@thinkbrg.com Jerry Lewandowski
More informationUnitedHealthcare: Out-of-Network Providers Upcoding Selected Evaluation and Management Services. New York State Health Insurance Program
New York State Office of the State Comptroller Thomas P. DiNapoli Division of State Government Accountability UnitedHealthcare: Out-of-Network Providers Upcoding Selected Evaluation and Management Services
More informationRidgecrest Regional Hospital Compliance Manual
Printed copies are for reference only. Please refer to the electronic copy for the latest version. REVIEWED DATE: 06/02/2014 REVISED DATE: 07/02/2013 EFFECTIVE DATE: 10/17/2007 DOCUMENT OWNER: APPROVER(S):
More informationTexas Vendor Drug Program. Pharmacy Provider Procedure Manual Pricing & Reimbursement. Effective Date. March 2018
Texas Vendor Drug Program Pharmacy Provider Procedure Manual Pricing & Reimbursement Effective Date March 2018 The Pharmacy Provider Procedure Manual (PPPM) is available online at txvendordrug.com/about/policy/manual.
More informationFinancial and Operational Benchmarking Trends & Techniques
Financial and Operational Benchmarking Trends & Techniques Susan Petrie Chief Operating Officer October 31, 2018 1 Capital Link - Overview Launched in 1995, nonprofit, HRSA national cooperative agreement
More informationHealthcare Financial Management Association Certification Program. Module I: The Business of Health Care Learner s Guide
Healthcare Financial Management Association Certification Program Module I: The Business of Health Care Learner s Guide For examination period beginning June 2015 1 Course 1 - The Big Picture Learning
More informationTHIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE
THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE Donna Lee Yesner Morgan Lewis and Bockius Phone : 202.739.5887 Email: dyesner@morganlewis.com www.morganlewis.com BACKGROUND In
More informationBERKELEY RESEARCH GROUP. Executive Summary
Executive Summary Within the U.S. healthcare system, the flow of dollars in the pharmaceutical marketplace is a complex process involving a variety of stakeholders and myriad rebates, discounts, and fees
More informationChallenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare
Challenges in High Dollar Drugs Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Disclosure I have no relevant conflicts of interest to disclose Learning
More informationAssessing ACA Issues - The 40% Excise Tax and Other Employer Implications
Assessing ACA Issues - The 40% Excise Tax and Other Employer Implications April, 2016, IPMA-Employer Training Edward A. Kaplan, Segal Consulting Copyright 2016 by The Segal Group, Inc. All rights reserved.
More informationAnalysis of the New Medicare Part D Drug Benefit and Changes to Medicare Part B Reimbursement: New Rules of the Road
National Medicare Prescription Drug Congress Analysis of the New Medicare Part D Drug Benefit and Changes to Medicare Part B Reimbursement: New Rules of the Road T. Reed Stephens Health Care Practice Group
More informationTX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement
January 31, 2014 VIA ELECTRONIC SUBMISSION Vendor Drug Program Medicaid/CHIP Division 4900 N. Lamar Austin, Texas 78751 RE: TX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement
More informationHealth Care Cost Transparency in Minnesota
Health Care Cost Transparency in Minnesota Julie Sonier, President MN Community Measurement October 25, 2018 1 MN Community Measurement: Who We Are and What We Do Multi-stakeholder collaborative Activities
More informationQuarterly Report As of December 31, 2018 and for the three and six months ended December 31, 2018
Quarterly Report As of December 31, 2018 and for the three and six months ended December 31, 2018 Table of Contents Part I: Overview... 1 Part II: Leadership Changes... 1 Part III: Strategic Acquisitions...
More informationQ Formulary Performance:
Insights Executive Briefing Issue 10, 2016 Q1 2016 Performance: Key Data to Consider as You Look Ahead to 2017 Increasingly our clients see proactive, dynamic formulary management as a necessary response
More informationSavings Generated by New York s Medicaid Pharmacy Reform
Savings Generated by New York s Medicaid Pharmacy Reform Sponsored by: Pharmaceutical Care Management Association Prepared by: Special Needs Consulting Services, Inc. October 2012 Table of Contents I.
More informationMEDICARE PLAN PAYMENT GROUP
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 MEDICARE PLAN PAYMENT GROUP Date: May 30, 2018 To: From: All Part D
More informationUpdate. The authors of this article are all consultants with Huron Consulting Group, which serves the continuum of life sciences organizations
Life Science Compliance Update REPRINTED FROM U.S. EDITION Volume 2.1 February 2016 Your Special Relationships Specialty Pharmacies and 5 Thoughtful Controls to Consider public advocates, and the media
More informationIncreasing pressure on PBMs to identify fraudulent providers
Increasing pressure on PBMs to identify fraudulent providers How PBMs can use data, analytics and advanced technology to reduce their risk In July 2017, the Justice Department arrested more than 400 people
More informationProjected Impacts of Adopting a Pharmacy Carve-In Approach Within Medicaid Capitation Programs
Projected Impacts of Adopting a Pharmacy Carve-In Approach Within Medicaid Capitation Programs Sponsored by: Medicaid Health Plans of America Prepared by: The Lewin Group Date: February 2011 Table of Contents
More informationHealth Care Fraud for Physicians
Health Care Fraud for Physicians UNM Family Medicine Residency Program May 25, 2011 Or... Why I Should Have Never Become A Doctor In The First Place Fraud Fraud vs. Abuse Intentional deception or misrepresentation
More informationOverview of October 24, 2013 Final Rule on Program Integrity: Exchange, Premium Stabilization Programs, and Market Standards
Overview of October 24, 2013 Final Rule on Program Integrity: Exchange, Premium Stabilization Programs, and Market Standards November 1, 2013 Overview of October 24, 2013 Final Rule on Program Integrity:
More informationMedicare s Shared Savings Program: Accountable Care Organizations Proposed Rule
Medicare s Shared Savings Program: Accountable Care Organizations Proposed Rule On March 31, 2011, the Centers for Medicare and Medicaid Services (CMS) issued its proposed rule on Medicare s Shared Savings
More informationOverview of Coverage of Drugs Under the Medicaid Medical Benefit
Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008 Amanda Bartelme Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Medical vs. Pharmacy
More informationRisk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study
Risk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study Presented by Bill O Brien, FSA, MAAA Consulting Actuary Milliman Houston, TX (832) 878-4078 Preconference I Agenda
More informationRe: Comments on proposed rule for the Medicare Shared Savings Program: Accountable Care Organizations
June 6, 2011 Centers for Medicare & Medicaid Services Department of Health and Human Services Attn: CMS-1345-P PO Box 8013 Baltimore, MD 21244-8013 Re: Comments on proposed rule for the Medicare Shared
More informationFlorida Agency for Health Care Administration AG Federal Awards Audit (Report# ) Six-Month Status Report as of September 30, 2014
Six-Month Status Report Finding# 2013-001 Recommendation Management Response The FAHCA Bureau of Finance and Accounting (Bureau) did not appropriately record in the correct funds the receivables resulting
More informationPatricia Gray, J.D., LL.M. Health Law & Policy Institute University of Houston Law Center September 27, 2012
Patricia Gray, J.D., LL.M. Health Law & Policy Institute University of Houston Law Center September 27, 2012 the ACA has put the nation on a path that will transform the nation s sick care system into
More informationMedicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary
Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary The Centers for Medicare & Medicaid Services (CMS) on February 2, 2012 published in the Federal Register a proposed rule
More information